While FTO has been shown to play an important role in leukemia [87], it is possible that additional RMPs such as HENMT1, which is drastically dysregulated in this cancer type, might constitute a better drug target to inhibit leukemogenesis (Fig. 4). Here, FTO is linked to cancer.